CN112839659A - 复发性滤泡性淋巴瘤的治疗 - Google Patents

复发性滤泡性淋巴瘤的治疗 Download PDF

Info

Publication number
CN112839659A
CN112839659A CN201980067638.8A CN201980067638A CN112839659A CN 112839659 A CN112839659 A CN 112839659A CN 201980067638 A CN201980067638 A CN 201980067638A CN 112839659 A CN112839659 A CN 112839659A
Authority
CN
China
Prior art keywords
compound
mixture
pharmaceutically acceptable
acceptable salt
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067638.8A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼尔·P·戈尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lite Strategy Inc
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of CN112839659A publication Critical patent/CN112839659A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980067638.8A 2018-08-14 2019-08-13 复发性滤泡性淋巴瘤的治疗 Pending CN112839659A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862718926P 2018-08-14 2018-08-14
US62/718,926 2018-08-14
US201962836507P 2019-04-19 2019-04-19
US62/836,507 2019-04-19
PCT/US2019/046408 WO2020036997A1 (en) 2018-08-14 2019-08-13 Treatment of relapsed follicular lymphoma

Publications (1)

Publication Number Publication Date
CN112839659A true CN112839659A (zh) 2021-05-25

Family

ID=69525835

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067638.8A Pending CN112839659A (zh) 2018-08-14 2019-08-13 复发性滤泡性淋巴瘤的治疗

Country Status (14)

Country Link
US (1) US20210196725A1 (enExample)
EP (1) EP3836936A4 (enExample)
JP (1) JP2021534116A (enExample)
KR (1) KR20210043637A (enExample)
CN (1) CN112839659A (enExample)
AU (1) AU2019321526A1 (enExample)
BR (1) BR112021002734A2 (enExample)
CA (1) CA3109377A1 (enExample)
IL (1) IL280721A (enExample)
MA (1) MA53237A (enExample)
MX (1) MX2021001765A (enExample)
SG (1) SG11202101417XA (enExample)
TW (1) TW202021593A (enExample)
WO (1) WO2020036997A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869A1 (fr) * 2007-08-09 2009-02-13 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116544C2 (uk) * 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2919869A1 (fr) * 2007-08-09 2009-02-13 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
CN103582636A (zh) * 2011-03-28 2014-02-12 梅制药公司 （α-取代的芳烷基氨基和杂芳基烷基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑、含有其的药物组合物以及这些化合物在治疗增生性疾病中的用途
MA38462A1 (fr) * 2013-04-08 2017-10-31 Bayer Pharma AG Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement de lymphomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
毕锡文;陈廷超;姜文奇;: "利妥昔单抗在淋巴瘤维持治疗中的新进展", 中国肿瘤临床, no. 24 *

Also Published As

Publication number Publication date
WO2020036997A1 (en) 2020-02-20
US20210196725A1 (en) 2021-07-01
CA3109377A1 (en) 2020-02-20
MX2021001765A (es) 2021-04-19
BR112021002734A2 (pt) 2021-07-20
TW202021593A (zh) 2020-06-16
EP3836936A4 (en) 2022-05-18
IL280721A (en) 2021-03-25
SG11202101417XA (en) 2021-03-30
KR20210043637A (ko) 2021-04-21
JP2021534116A (ja) 2021-12-09
AU2019321526A1 (en) 2021-03-25
EP3836936A1 (en) 2021-06-23
MA53237A (fr) 2021-06-23

Similar Documents

Publication Publication Date Title
CN106660991B (zh) 抗增殖化合物及其使用方法
EP3515916B1 (en) Shp2 phosphatase inhibitors and methods of use thereof
CN111212643A (zh) 联合疗法
JP2021517116A (ja) 併用療法
TW201521725A (zh) 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
US20210196725A1 (en) Treatment of relapsed follicular lymphoma
US11712433B2 (en) Compositions comprising PKM2 modulators and methods of treatment using the same
CN112888441A (zh) B细胞恶性肿瘤的治疗
CN112839651A (zh) 联合疗法
WO2020198067A1 (en) Pkm2 modulators and methods for their use
AU2015240094B2 (en) Combinations of cancer therapeutics
WO2025068461A1 (en) Guanfacine derivatives and their use in treating cancer
TW202509035A (zh) Ｊａｋ抑制劑化合物及晶型
HK40029947A (en) Antiproliferative compounds and methods of synthesizing thereof
HK40105245A (en) Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
CN118891255A (zh) 新化合物及其抑制检查点激酶2的用途
WO2021155185A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525